Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details)

Commitments and Contingencies (Details)				1 Months Ended				3 Months Ended		12 Months Ended			16 Months Ended	40 Months Ended	64 Months Ended
Commitments and Contingencies (Details)	Apr. 01, 2021 USD ($)	Mar. 25, 2021 USD ($)	Feb. 03, 2020 USD ($) milestone	Aug. 31, 2019 USD ($)	Jul. 31, 2019 USD ($)	Sep. 30, 2018 USD ($) therapy	Aug. 31, 2017 USD ($)	Mar. 31, 2021 USD ($)	Mar. 31, 2020 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)	Dec. 31, 2018 unit $ / shares	Apr. 30, 2021 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2023 USD ($)
Operating Leased Assets [Line Items]
Total revenue								$ 473,000	$ 2,754,000
Potential future regulatory milestone							$ 20,000,000.0
Payment received					$ 2,000,000.0
Period after public launch to terminate agreement					3 years
Percentage of net present value of royalty payments					75.00%
Aevi
Operating Leased Assets [Line Items]
Milestone payment								0
Aevi
Operating Leased Assets [Line Items]
Number of milestones \| milestone			2
Contingent consideration			$ 6,500,000						$ 6,500,000
Aevi \| Milestone One
Operating Leased Assets [Line Items]
Contingent consideration			2,000,000.0
Aevi \| Milestone Two
Operating Leased Assets [Line Items]
Contingent consideration			$ 4,500,000
Ichorion
Operating Leased Assets [Line Items]
Number of milestones \| milestone			3
Contingent consideration						$ 15,000,000.0
Milestone payment								0
Ichorion \| Milestone One \| Forecast
Operating Leased Assets [Line Items]
Milestone payment														$ 6,000,000.0
Ichorion \| Milestone Two \| Forecast
Operating Leased Assets [Line Items]
Milestone payment															$ 5,000,000.0
Ichorion \| Milestone Three \| Forecast
Operating Leased Assets [Line Items]
Milestone payment															$ 4,000,000.0
Millipred \| Teva \| Subsequent Event
Operating Leased Assets [Line Items]
Semi-annual license payment													$ 75,000
Percent of net profit for installment payments	50.00%
Installment payment	$ 500,000
CERC-611
Operating Leased Assets [Line Items]
Potential milestone payment				$ 7,500,000
Potential milestone revenue threshold				750,000,000.0
Potential milestone payment two				12,500,000
Potential milestone revenue threshold two				1,300,000,000
License obligations				$ 1,300,000
CERC-611 \| Armistice
Operating Leased Assets [Line Items]
Revenue from related parties											$ 100,000
License
Operating Leased Assets [Line Items]
Total revenue							$ 25,000,000.0
CERC-002 KKC License Agreement
Operating Leased Assets [Line Items]
Potential milestone payment		$ 75,000,000
License agreement fees		$ 10,000,000.0						10,000,000.0
Percent of payments received from sublicensing		30.00%
CERC-006 Astellas License Agreement
Operating Leased Assets [Line Items]
Potential milestone payment								5,500,000
License agreement fees								500,000
Milestone payment recognized								500,000
CERC-007 AstraZeneca License Agreement
Operating Leased Assets [Line Items]
Potential milestone payment								$ 162,000,000
Milestone payment recognized										$ 1,500,000
CERC-801, CERC-802, and CERC-803 \| Ichorion
Operating Leased Assets [Line Items]
Number of preclinical therapies \| therapy						3
CERC-913 \| Ichorion
Operating Leased Assets [Line Items]
Number of preclinical therapies \| therapy						1
TRIS Pharma \| Karbinal Agreement
Operating Leased Assets [Line Items]
Minimum quantity required \| unit												70,000
Make whole payment per unit (in dollars per share) \| $ / shares												$ 30